Full-Time

Associate Architect

Infrastructure and Operations

Confirmed live in the last 24 hours

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

Develops targeted therapies for cancer and allergies

No salary listed

Senior

Cambridge, MA, USA

Category
DevOps & Infrastructure
Database Administration
Cloud Engineering
Requirements
  • 6+ years of relevant technical experience and 2+ years of experience in a senior role
  • Bachelor’s degree in a related field or equivalent experience
Responsibilities
  • Lead or participate in a cross functional team to plan and design information technology solutions
  • Identify and implement strategies to optimize infrastructure performance, capacity, and efficiency
  • Troubleshoot and resolve infrastructure issues quickly and effectively, minimizing downtime and impact on business operations.
  • Lead cloud infrastructure for corporate application and web servers to ensure high availability and optimal performance
  • Design scalable cloud infrastructure for our data analyses and other informatics pipelines
  • Maintain production databases and application servers to support research and development efforts
  • Mitigate security issues stemming from regular audits of IT systems as needed
  • Oversee regular maintenance and testing of remote disaster recovery infrastructure
  • Lead and participate in business continuity planning and implementation with a cross functional team
  • Lead efforts to improve and optimize existing processes
  • Act as mentor and escalation point for colleagues. Lead initiatives with manageable risks and resource requirements
  • Collaborate with other IT teams, business units, and stakeholders to understand their needs and ensure infrastructure solutions meet their requirements
  • Maintain accurate and up-to-date documentation of infrastructure configurations, processes, and procedures.
  • Perform other responsibilities as assigned
Desired Qualifications
  • Proficiency in leading and designing cloud-first infrastructure
  • Proficiency in handling mixed Windows, Linux, and MacOS environments
  • Proficiency in scripting (unix shell/powershell/aws-cli)
  • Proficiency in managing Microsoft 365, including Entra ID, Intune, Exchange Online, Teams, and SharePoint
  • Proficiency in maintaining Oracle, SQL Server, PostgresSQL, and MySQL server databases
  • Proficiency in supervising network monitoring/security solutions such as Zabbix, Crowdstrike, and Zscaler
  • Proficiency managing campus network solutions including routing, switching, firewalling, and wireless access. Experience with Cisco, FortiNet, and Extreme is a plus.
  • Familiarity with maintaining a range of web servers, such as IIS, Nginx, Tomcat, and JBoss
  • Experience with infrastructure-as-code solutions such as CloudFormation or Terraform is a plus
  • Resourcefulness/Flexibility – The ability to adapt to working optimally within a variety of situations; adapts to change and to changes in job demands
  • Communication and Partnership – Ability to optimally express ideas in written and oral context; collaboration, team-building skills and interpersonal skills; genuine desire to be on a team and contribute to organizational and team goals
  • Effective Planning – Demonstrated effective time management skills and execution
  • Perseverance – Pursues tasks with energy, drive and initiative; comfortable in an accountable environment where you can make an impact
  • Problem Solving – Ability to understand a situation or problem by breaking it down into smaller pieces using a detailed approach and to identify patterns and connections between situations that are not obviously related
  • Relationship Building – Builds productive working relationships across a diverse spectrum of people
  • Commitment to our Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

Blueprint Medicines develops biopharmaceuticals aimed at treating serious medical conditions, focusing on allergy/inflammation and oncology/hematology. Their medicines work by targeting the underlying causes of diseases, utilizing extensive scientific knowledge and drug discovery methods. Unlike many competitors, Blueprint Medicines has a strong track record with two approved drugs and is advancing a diverse pipeline that includes treatments for mast cell diseases and various cancers. The company's goal is to alleviate human suffering by creating effective therapies while fostering a collaborative and inclusive work environment for its employees.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on personalized medicine boosts demand for Blueprint's targeted therapies.
  • FDA initiatives expedite approval for rare disease treatments, benefiting Blueprint's pipeline.
  • Collaborations with academic institutions expand Blueprint's R&D capabilities.

What critics are saying

  • Competition from Agendia's genomic testing may impact Blueprint's market share.
  • New Chief Business Officer may disrupt current business operations.
  • Reliance on AYVAKIT for revenue growth poses risk if market conditions change.

What makes Blueprint Medicines unique

  • Blueprint Medicines leads in mast cell-targeted therapies with AYVAKIT and BLU-808.
  • AYVAKIT shows long-term efficacy and safety in treating indolent systemic mastocytosis.
  • BLU-808 offers a wide therapeutic window as a wild-type KIT inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Agendia
Apr 24th, 2025
Agendia Spotlights New Data on Genomic Testing at 26th American Society of Breast Surgeons Annual Meeting

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS - April 24, 2025 - Agendia(R), Inc., announced today that new MammaPrint and BluePrint data and their ability to inform axillary surgery decisions in the neoadjuvant setting will be presented at the 26th American Society of Breast Surgeons Annual Meeting (ASBrS), taking place in Las Vegas, NV, April 30 - May 4, 2025.

ETF Daily News
Mar 8th, 2025
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Proficio Capital Partners LLC makes new $1.01 million investment in Blueprint Medicines Co. (NASDAQ:BPMC).

Defense World
Mar 7th, 2025
Truist Financial Corp Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Truist Financial Corp makes new investment in Blueprint Medicines Co. (NASDAQ:BPMC).

Medical Update Online
Mar 4th, 2025
Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025

Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025.

PR Newswire
Feb 28th, 2025
Blueprint Medicines Highlights Leading Portfolio Of Mast Cell-Targeted Therapies At 2025 Aaaai / Wao Joint Congress

-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy ---- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course ---- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor --CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. The presentations include three-year median follow-up data from the registrational PIONEER trial demonstrating the strong long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), and real-world evidence further characterizing the substantial burden of the disease, highlighting the urgency to treat. In addition, the company will report positive data from the Phase 1 healthy volunteer trial evaluating BLU-808, an investigational, highly potent and selective oral inhibitor of wild-type KIT, consistent with top-line data previously announced in January 2025. A total of 14 data presentations, including two oral presentations, will be reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress being held February 28-March 3 in San Diego."We are incredibly proud to showcase our mast cell therapy portfolio at AAAAI / WAO, with 14 presentations highlighting more than a decade of leadership and collaboration with the mast cell disease community, including renowned medical institutions pioneering innovative research and multi-disciplinary patient care," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "In ISM, new data have reinforced that AYVAKIT was very well-tolerated after multiple years of treatment, with a low discontinuation rate and safety results that have remained consistent with the safety profile from the placebo-controlled study as summarized in the FDA-approval label